GILEAD Sciences GmbHSince 1987, Gilead Sciences has worked to discover, develop and commercialize medications to advance the care of patients suffering from life-threatening diseases in areas of unmet medical need. ...Since
Cayston is administered with the Altera® Nebulizer System, a portable, drug-specific delivery device using the eFlow® Technology Platform, developed by PARI Pharma GmbH. (EU approval, 2009; U.S. approval, 2010.) Tamiflu (oseltamivir phosphate) 75 mg is an influenza neuraminidase inhibitor ...
Product Sales Excluding Veklury Increased Year-Over-Year by 8% for Full Year 2022 Biktarvy Sales Increased Year-Over-Year by 20% for Full Year 2022 Oncology Sales Increased Year-Over-Year by 71% for Full Year 2022 Gilead Sciences, Inc. (Nasdaq: GILD) ann
吉利德科学公司(Gilead Sciences)总部位于美国加利福尼亚,是一家以研究为基础,从事药品开发和销售的生物制药公司。吉利德重点治疗领域包括艾滋病、肝脏疾病、血液和肿瘤疾病、炎症和呼吸系统疾病以及心血管疾病。2020年,吉利德名列福布斯全球企业20...
Adjustments include integration expenses, contingent consideration fair value adjustments and other expenses associated with Gilead’s acquisitions of MYR GmbH, MiroBio, Ltd., Tmunity Therapeutics, Inc., XinThera, Inc. and CymaBay Therapeutics, Inc. (3) Represents discrete and...
Foster City, California,Saturday, March 6, 2021, 13:30 Hrs [IST] Gilead Sciences Inc announced the completion of the previously announced transaction to acquire MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. ...
8Gilead Sciences GmbH子公司 9Gilead Apollo, LLC子公司 10Gilead Ireland Research UC子公司 11Gilead Sciences Malaysia Sdn. Bhd.子公司 12Gilead Sciences Canada, Inc.子公司 13Gilead Sciences Korea Limited子公司 14Gilead Calistoga, LLC子公司
Hepcludex®(Bulevirtide)是由德国生物技术公司MYR GmbH开发的一种first-in-class病毒进入抑制剂,可通过与 NTCP 结合来防止再生细胞的感染和病毒在肝内的传播。其中,NTCP 是肝细胞表面上一种重要的HBV/HDV受体。 图1.Hepcludex®作用机制 Hepcludex®(Bulevirtide)最初于2020-07获欧盟的有条件批准,用于为...
根据最新消息显示,吉利德科学(Gilead Sciences)聘请了安进(Amgen)研发执行官Flavius Martin来负责运营吉利德的研发部门。 入职后,Martin将担任吉利德研发副总裁,并将直接向吉利德董事长兼首席执行官Daniel O'Day汇报。Martin将接替任职30余年、宣布退休的Bill Lee博士,从4月12日开始负责运行吉利德公司的整个研发业务。Ma...
Hepcludex®(Bulevirtide)是由德国生物技术公司MYR GmbH开发的一种first-in-class病毒进入抑制剂,可通过与 NTCP 结合来防止再生细胞的感染和病毒在肝内的传播。其中,NTCP 是肝细胞表面上一种重要的HBV/HDV受体。 图1.Hepcludex®作用机制 Hepcludex®(Bulevirtide)最初于2020-07获欧盟的有条件批准,用于为...